Craig Kallman reports 6.0% stake in PAVmed
PAVmed Inc. Schedule 13G reports that the Craig Kallman 2015 Living Trust and Craig Kallman together beneficially own 384,616 shares of PAVmed common stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
PAVmed Inc. Schedule 13G reports that the Craig Kallman 2015 Living Trust and Craig Kallman together beneficially own 384,616 shares of PAVmed common stock. The filing states this equals 6.0% of the class, based on 6,383,089 shares outstanding as of March 27, 2026.
The Trust holds sole voting and sole dispositive power over the 384,616 shares. The Reporting Persons filed a Joint Filing Agreement and note Mr. Kallman controls the Trust.
Insights
Ownership disclosure shows a significant 6.0% stake held via a family trust.
The filing identifies the Craig Kallman 2015 Living Trust and Craig Kallman as joint reporting persons with sole voting and dispositive power over 384,616 shares. The stake is calculated from 6,383,089 shares outstanding as of March 27, 2026.
Because the position is held in a trust controlled by Mr. Kallman, subsequent filings or amendments could clarify any changes; timing for any future transactions is not stated in the excerpt.
Key Figures
Key Terms
Schedule 13G regulatory
beneficially owns financial
Joint Filing Agreement regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What stake does Craig Kallman hold in PAVmed (PAVM)?
What document governs joint reporting for these holdings?
How was the percent ownership calculated in the filing?
AI-generated analysis. How Rhea-AI works. Not financial advice.